# Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

> **NCT07134998** · PHASE1 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 153 (estimated)

## Conditions studied

- Advanced KRAS G12D Mutant Solid Tumors

## Interventions

- **DRUG:** HRS-6093

## Key facts

- **NCT ID:** NCT07134998
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-16
- **Primary completion:** 2028-05
- **Final completion:** 2028-12
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134998, "Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07134998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*